Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is a small oligopeptide drug derived from angiotensin IV. It was first developed in the early 2000s by Joseph Harding and his team at Washington State University. They were inspired by the fact that hepatocyte growth factor (HGF) is a potent neurotrophic factor that plays an important role in the development and maintenance of the nervous system. HGF also has neuroprotective and regenerative effects, which suggests that it could be a promising target for the treatment of neurodegenerative diseases such as Alzheimer’s disease.
Harding and his team designed Dihexa to be a small molecule that could easily cross the blood-brain barrier and target HGF receptors in the brain. In animal studies, Dihexa was shown to improve cognitive function, reduce amyloid beta plaques, and promote the growth of new neurons in the hippocampus, a brain region that is critical for learning and memory.
In 2008, Harding and his team founded the company M3 Biotechnology to commercialize Dihexa. M3 Biotechnology conducted a Phase 1 clinical trial of Dihexa in patients with Alzheimer’s disease in 2012. The trial showed that Dihexa was safe and well-tolerated.
In 2014, M3 Biotechnology was acquired by the Japanese pharmaceutical company Eisai. Eisai is currently conducting a Phase 2 clinical trial of Dihexa in patients with Alzheimer’s disease. The trial is expected to be completed in 2023.
Potential benefits of Dihexa
Dihexa is a promising new drug for the treatment of Alzheimer’s disease and other neurological disorders. It has the potential to improve cognitive function, reduce amyloid beta plaques, promote the growth of new neurons, and protect neurons from damage.
Safety and side effects
Dihexa has been shown to be safe and well-tolerated in clinical trials. However, some people may experience side effects such as nausea, vomiting, diarrhea, and headache. Dihexa is not recommended for pregnant or breastfeeding women.
Dihexa is a promising new drug for the treatment of Alzheimer’s disease and other neurological disorders. It is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease, and the results of these trials are eagerly awaited.
